Literature DB >> 2894204

Circulating inhibitor bound elastase in patients with ankylosing spondylitis and rheumatoid arthritis and the influence of sulphasalazine treatment.

N Feltelius1, R Hällgren.   

Abstract

The plasma concentration of granulocyte elastase in complex with alpha 1 proteinase inhibitor was determined in 42 patients with ankylosing spondylitis (AS) and 33 patients with rheumatoid arthritis (RA). Significantly raised levels of plasma elastase were found in patients with RA, whereas patients with AS had normal values. No correlation was seen between the elastase values and erythrocyte sedimentation rate (ESR), serum haptoglobin, immunoglobulins, or polymorphonuclear cell (PMN) count in either of the patient groups. A correlation was found between the Ritchie index and plasma elastase in patients with RA. After three months' treatment with sulphasalazine a clinical improvement was seen and this paralleled a reduction of the acute phase reaction in both patient groups. A reduction of the circulating elastase values was seen in the patients with RA, whereas no change was seen in patients with AS.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2894204      PMCID: PMC1003435          DOI: 10.1136/ard.47.1.10

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  20 in total

1.  1958 Revision of diagnostic criteria for rheumatoid arthritis.

Authors:  M W ROPES; G A BENNETT; S COBB; R JACOX; R A JESSAR
Journal:  Bull Rheum Dis       Date:  1958-12

2.  Release of granulocyte proteinases during hemodialysis.

Authors:  W H Hörl; M Jochum; A Heidland; H Fritz
Journal:  Am J Nephrol       Date:  1983 Jul-Aug       Impact factor: 3.754

3.  Polymorphonuclear cell motility, ankylosing spondylitis, and HLA B27.

Authors:  C T Pease; J N Fordham; H L Currey
Journal:  Ann Rheum Dis       Date:  1984-04       Impact factor: 19.103

4.  Leukocyte elastase release during blood coagulation. A potential mechanism for activation of the alternative fibrinolytic pathway.

Authors:  E F Plow
Journal:  J Clin Invest       Date:  1982-03       Impact factor: 14.808

5.  Enhanced neutrophil migration in vivo HLA B27 positive subjects.

Authors:  P Koivuranta-Vaara; H Repo; M Leirisalo; U Kiistala; T Osterman; H Vapaatalo
Journal:  Ann Rheum Dis       Date:  1984-04       Impact factor: 19.103

6.  Eosinophil cationic protein in inflammatory synovial effusions as evidence of eosinophil involvement.

Authors:  R Hällgren; A Bjelle; P Venge
Journal:  Ann Rheum Dis       Date:  1984-08       Impact factor: 19.103

7.  Elastase activity in serum and synovial fluid of patients with connective tissue disorders.

Authors:  L A Cooke; F C Hay; D A Isenberg
Journal:  J Rheumatol       Date:  1984-10       Impact factor: 4.666

8.  Immunoreactive granulocyte elastase in rheumatoid synovial fluid and membrane.

Authors:  L Ekerot; K Ohlsson
Journal:  Scand J Plast Reconstr Surg       Date:  1982

9.  Enzyme-linked immunoassay for human granulocyte elastase in complex with alpha 1-proteinase inhibitor.

Authors:  S Neumann; N Hennrich; G Gunzer; H Lang
Journal:  Adv Exp Med Biol       Date:  1984       Impact factor: 2.622

10.  Granulocyte survival in synovial exudate of patients with rheumatoid arthritis and other inflammatory joint diseases.

Authors:  J W Hollingsworth; E R Siegel; W A Creasey
Journal:  Yale J Biol Med       Date:  1967-04
View more
  4 in total

1.  Enumeration of IgA producing cells by the enzyme linked immunospot (ELISPOT) technique to evaluate sulphasalazine effects in inflammatory arthritides.

Authors:  N Feltelius; S Gudmundsson; L Wennersten; O Sjöberg; R Hällgren; L Klareskog
Journal:  Ann Rheum Dis       Date:  1991-06       Impact factor: 19.103

2.  Measurement of plasma concentrations of polymorphonuclear elastase-alpha 1 proteinase inhibitor (elastase-alpha 1 antitrypsin) in patients with rheumatoid arthritis: interference by rheumatoid factor.

Authors:  R E Banks; S W Evans; K F Taylor; H A Bird; J T Whicher
Journal:  Ann Rheum Dis       Date:  1990-01       Impact factor: 19.103

3.  Plasma and synovial fluid levels of granulocytal elastase-alpha-1-protease inhibitor complex in patients with rheumatoid arthritis.

Authors:  K Kuramitsu; A Yoshida
Journal:  Rheumatol Int       Date:  1990       Impact factor: 2.631

Review 4.  Sulfasalazine. A review of its pharmacological properties and therapeutic efficacy in the treatment of rheumatoid arthritis.

Authors:  C P Rains; S Noble; D Faulds
Journal:  Drugs       Date:  1995-07       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.